Gyrolab Spin Blog

Jan 15, 2020 7:35:53 AM

Putting a new spin on immunoassays for cell and gene therapy – Part 2

Careful platform choice generates data with higher quality to support DOE

 

Putting a new spin on immunoassays for cell and gene therapy – Part 2Harnessing the power of cell and gene therapy involves a large range of analytical methods that can deliver robust results to support rapid data driven decision-making. One assay development team has used immunoassays to track a transgene IgG product. Their choice of immunoassay platform enabled them to generate high quality data that supported Design of Experiments to quickly optimize cell culture.

Read More

Topics: Assay Development, Gene therapy, Gyrolab system


Jan 15, 2020 7:35:35 AM

Putting a new spin on immunoassays for gene therapy – Part 1

How to detect vector immunogenicity 24× faster and with 10× less sample

 

Putting a new spin on immunoassays for gene therapy – Part 1Cell and gene therapy promises to revolutionize medicine by correcting underlying genetic causes of disease or conferring new functions to cells to combat disease and has already seen spectacular successes in health care, ranging from curing rare eye diseases, to the treatment of sickle cell disease and a number of cancers. Immunoassays can be important analytical tools in cell and gene therapy and the careful choice of an immunoassay platform can improve productivity by boosting workflows, data quality and greatly reducing the consumption of precious samples, for example in detecting antibodies against lentivirus vectors that are commonly used in cell and gene therapy.

Read More

Topics: ADA, Gene therapy, Gyrolab system


Jun 11, 2019 2:37:58 PM

Next generation antibody therapeutics move into prokaryotes

Smaller, simpler biotherapeutics pave the way for new production methods

 

Escherichia coliMammalian expression systems have driven the rise of biotherapeutics. Their ability to introduce proper protein folding, post-translational modifications, and product assembly means that they are currently used to produce almost all therapeutic antibodies to ensure correct structure and minimize the risk of immunogenicity. But the advent of smaller, simpler biotherapeutics means that prokaryote expression systems such Escherichia coli (E. coli) are playing a new role in antibody therapy. These bacteria can deliver high expression levels, with simpler bioprocessing at a lower cost together with an extensive molecular toolbox based on well-characterized genetics. This development is increasing the need for sensitive methods to monitor bioprocess development and manufacturing based on E. coli-based expression systems, including the sensitive analysis of host cell proteins. 

Read More

Topics: HCP, impurity testing, Gyrolab system, Host Cell Proteins


May 23, 2019 9:36:37 AM

Fighting the obesity pandemic

Novel approaches include bifunctional peptide-based drugs

 

scale-lowObesity has become a devastating pandemic, with 108 million obese children and 604 million obese adults worldwide in 2015, and the problem is increasing (1). The result is an escalation in serious conditions such as type 2 diabetes mellitus (T2DM), cardiovascular disease, hypertension, dyslipidemia and several cancer forms, mainly gastrointestinal. Obesity is very difficult to treat through life style changes and surgery has become the most effective and long-lasting route to sustained weight loss, although it is only available to a small subset of individuals, and is both costly and risky. The search for more widely applicable treatment has driven the development of peptide-based pharmaceuticals that can meet key challenges of obesity, including control over satiety, blood sugar and LDL cholesterol levels.   

Read More

Topics: solid-phase peptide synthesis, Obesity, immunoassay, Symphony peptide synthesizer, GLP-1, Diabetes, Gyrolab system